DEAFinal Rule
Expansion of Buprenorphine Treatment via Telemedicine Encounter
HealthcareOther
Ad Space (leaderboard)
Summary
This regulation allows doctors to prescribe buprenorphine, a medication that treats opioid addiction, through telemedicine (video calls and online visits) instead of requiring in-person appointments. This change makes addiction treatment more accessible to people in rural areas or those who have transportation challenges.
Key Points
- 1Doctors can now prescribe buprenorphine via telehealth visits, making it easier for patients to access addiction treatment without traveling to a clinic
- 2The rule expands access for people in underserved communities, including rural areas where addiction treatment options are limited
- 3Patients can receive ongoing medication management and check-ins remotely while still meeting legal and safety requirements
- 4This change was implemented by the DEA to address the opioid crisis by removing barriers that prevented people from getting help
- 5In-person visits may still be required for initial evaluations or specific situations, depending on state laws and individual patient needs
Impact Assessment
If you are a healthcare provider, this means you can now prescribe buprenorphine through telemedicine without requiring in-person visits, expanding your reach to patients in underserved areas.
Impact Level
Significant
Geographic Scope
National
Compliance Cost
Minimal
Who is Affected
Healthcare ProvidersConsumersTechnology Companies
Key Dates
Published
January 17, 2025
Regulatory Connections
Authorized By
Amends CFR Sections
21 CFR Part 1306
Other Documents in This Rulemaking (DEA-2023-0028)
This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.
The Digest Network
Ad Space (rectangle)